Researchers from Schmidt Science Fellows have unveiled a CRISPR-based technology that could detect antibodies from blood samples, paving the way for medical diagnostics to identify various pathogens, including the SARS-CoV-2 virus. The researchers created a protein self-assembly technique, which can be leveraged to develop new biomaterials and biosensors. In a study, the technology was able to identify antibodies attaching to proteins obtained from pathogens.
A new study led by the University of Birmingham has highlighted the need for new clinical risk management tools to prevent intensive care admissions and deaths of black, Asian and minority ethnic (BAME) patients with Covid-19-related pneumonia. Involving 3,671 patients, the study showed that 81.5% of ethnic minority Covid-19 patients from regions of highest air pollution deprivation were at more risk of hospital admissions versus 46.9% of Caucasians. It was observed that current tools to forecast or measure risk and manage the care of Covid-19-related pneumonia patients are inadequate and may underscore ethnic minority patients.
Go deeper with GlobalData
Medi Lifestyle’s indirect wholly owned subsidiaries, HealthPro Marketing and HealthPro Pharma, have entered exclusive agreements to sell and distribute Lansion Biotechnology’s SARS-CoV-2 Neutralizing Antibodies Test Kit and its LS-4000 Dry Fluorescence Immunoassay Analyser in Malaysia and Singapore. The test kit requires a minimal blood sample that can be placed on a test strip. Subsequently, a lateral flow test delivers a Covid-19 antibody qualitative result in several minutes. The test strip can be run on the LS-4000 Dry Fluorescence Immunoassay Analyser for a detailed quantitative analysis.
